Federal officials want to soften warning labels as new evidence eases old safety fears
The federal government wants to rewrite the warning labels on testosterone treatments for men, a move that could make the therapy easier to get. The change is not final, and doctors stress that men still need a careful diagnosis before starting anything.
What the government is changing
The US Department of Health and Human Services asked on Thursday for revisions to the labels on testosterone replacement therapies, pointing to fresh evidence about their safety and benefits. One proposed change would drop a line saying the treatment’s safety and effectiveness have not been proven in men with age related low testosterone.
The agency, led by Secretary Robert F. Kennedy Jr., also wants to update guidance on prostate cancer risk and ease warnings about enlarged prostate. Officials framed the request as a way to give patients and physicians clearer information so they can make better informed decisions.
For now this is only a request, and nothing has officially changed. Dr. Jamin Brahmbhatt, a urologist and men’s health expert at Orlando Health in Florida, described the move as science finally catching up to reality, while cautioning that removing a warning is not the same as saying every man should be on the therapy.
3 shifts in the safety picture
The proposed updates touch the three concerns that have long shaped how testosterone is prescribed.
- Heart risk. Back in 2015, regulators added language saying the treatment’s safety and effectiveness had not been established for men with a form of low testosterone, partly over worries about possible heart problems. Since then, a large trial of more than 5,200 men found no meaningful rise in major events such as heart attack or stroke among those on therapy.
- Prostate cancer. Current labels generally warn against the treatment in men with known or suspected prostate cancer and caution that it may raise the risk. Newer data has not generally shown that increase, and the proposed labels would advise against the therapy only in men whose prostate cancer has already spread.
- Enlarged prostate. Today’s labels warn that the treatment may worsen a benign enlarged prostate. A new FDA review found no sign of that in men with mild to moderate symptoms. For men with severe symptoms the evidence is thinner, so the updated labels would call for ongoing monitoring during treatment.
Not a green light for everyone
Doctors are clear that easier labels do not mean the treatment is right for every man. Brahmbhatt stresses that testosterone is a medical therapy and not a wellness product, and that guardrails should stay in place. He is also hopeful that clearer labels could help more insurers cover it for the men who truly need it.
Dr. Adam Baumgarten, an associate professor of urology at the University of Alabama at Birmingham, said the update has been a long time coming, but he echoed that it is not a signal for casual use. The therapy still calls for a clear diagnosis based on symptoms and consistently low levels, along with regular lab follow up.
The benefits can be real for the right patient. Dr. Eddie Hackler III, an Atlanta cardiologist, said the treatment can improve libido, sexual function, mood and energy and help correct anemia, as long as the diagnosis is sound. He also noted possible downsides, including acne and skin reactions, blood clots, irregular heart rhythms, reduced sperm production and a slight rise in blood pressure.
What counts as low testosterone
Providers generally treat a level below 300 nanograms per deciliter as low, though both doctors note there is no single number that fits every man. Normal readings shift with age and can stretch from around 300 to more than 800, depending on the guidelines used and the lab doing the test.
Before prescribing, Brahmbhatt looks for a level that is genuinely low, confirmed by two separate morning blood draws when testosterone naturally peaks, and matched to real symptoms such as low sex drive, fatigue, trouble with erections or loss of muscle. For a man whose levels are already normal and who is chasing a boost he saw promoted online, he warns the risks may outweigh any benefit, since the treatment can suppress sperm production, thicken the blood and leave a long term prostate picture that is still not fully clear.
Story credit: CNN